Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

M. Frigeni, C. Besson, C. Visco, H. Fontaine, M. Goldaniga, M. Visentini, A. Pulsoni, H.A. Torres, J. Peveling-Oberhag, R. Rossotti, F. Zaja, L. Rigacci, M. Merli, C. Dorival, C. Alric, F. Piazza, M. Gentile, A. Ferrari, M. Pirisi, L. NassiS. Rattotti, A. Frustaci, M. Milella, E. Cencini, I. Defrancesco, V.V. Ferretti, R. Bruno, O. Hermine, L. Arcaini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1462-1466
Number of pages5
JournalLeukemia
Volume34
Issue number5
DOIs
Publication statusPublished - 2020

Keywords

  • antivirus agent
  • interferon
  • alpha interferon
  • adult
  • aged
  • antiviral therapy
  • Article
  • cancer growth
  • clinical feature
  • cohort analysis
  • comparative effectiveness
  • controlled study
  • diffuse large B cell lymphoma
  • disease association
  • female
  • follow up
  • hepatitis C
  • human
  • major clinical study
  • male
  • overall survival
  • priority journal
  • progression free survival
  • retrospective study
  • splenic marginal zone lymphoma
  • sustained virologic response
  • treatment duration
  • treatment response
  • B lymphocyte
  • comparative study
  • complication
  • drug effect
  • Hepacivirus
  • isolation and purification
  • lymphoproliferative disease
  • middle aged
  • mortality
  • pathology
  • prognosis
  • survival rate
  • very elderly
  • virology
  • young adult
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents
  • B-Lymphocytes
  • Female
  • Follow-Up Studies
  • Hepatitis C
  • Humans
  • Interferon-alpha
  • Lymphoproliferative Disorders
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Young Adult

Cite this